Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

ASP Isotopes (ASPI) Research & Development (2022 - 2025)

ASP Isotopes has reported Research & Development over the past 4 years, most recently at $6.8 million for Q4 2025.

  • On a quarterly basis, Research & Development rose 383.7% to $6.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was $12.4 million, a 293.69% increase, with the full-year FY2025 number at $12.4 million, up 293.69% from a year prior.
  • Research & Development reached $6.8 million in Q4 2025 per ASPI's latest filing, up from $3.1 million in the prior quarter.
  • The five-year high for Research & Development was $6.8 million in Q4 2025, with the low at $65168.0 in Q4 2023.
  • The 4-year median for Research & Development is $383176.5 (2022), against an average of $1.1 million.
  • Peak YoY movement for Research & Development: crashed 67.91% in 2023, then skyrocketed 2073.03% in 2024.
  • Tracing ASPI's Research & Development over 4 years: stood at $81635.0 in 2022, then decreased by 20.17% to $65168.0 in 2023, then skyrocketed by 2073.03% to $1.4 million in 2024, then surged by 383.7% to $6.8 million in 2025.
  • According to Business Quant data, Research & Development over the past three periods came in at $6.8 million, $3.1 million, and $879925.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.